Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib plus capecitabine versus trastuzumab plus capecitabine after local therapy for HER2-positive metastatic breast cancer with brain metastases
2010-022737-28Phase 4Completed
- Sponsor
- Leeds Teaching Hospitals NHS Trust
- Start
- Jan 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in breast cancer comparing Lapatinib plus capecitabine with Continued trastuzumab plus capecitabine (2 arms). Primary endpoint: Time to progression of central nervous system metastases. Started Jan 2011; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2010-022737-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022737-28.